The affected medications include: Semaglutide (Ozempic, Rybelsus, Wegovy) Liraglutide (Saxenda, Victoza) Tirzepatide (Mounjaro, Zepbound) New Warning Details The updated label now includes a subsection under "Warnings and Precautions" that states: "There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations." This warning highlights the potential risk of stomach contents entering the lungs during surgical procedures, even when patients have followed fasting guidelines
This cap was established when the health equity adjustment was finalized in performance year 2023 and was not designed to increase (or decrease) as the quality measure set expands (or contracts)
Potential Benefits: - Faster visible results in skin brightening - Boosts overall antioxidant levels in the body But remember: This should only be done by a licensed medical professional in a sterile setting
GLP-1 RAs are generally preferred after consideration of several factors when selecting additional drugs to manage glycemia, such as patient preferences, comorbidities, eGFR, and cost [18, 20]
